SG11201807868VA - Transfected t-cells and t-cell receptors for use in immunotherapy against cancers - Google Patents
Transfected t-cells and t-cell receptors for use in immunotherapy against cancersInfo
- Publication number
- SG11201807868VA SG11201807868VA SG11201807868VA SG11201807868VA SG11201807868VA SG 11201807868V A SG11201807868V A SG 11201807868VA SG 11201807868V A SG11201807868V A SG 11201807868VA SG 11201807868V A SG11201807868V A SG 11201807868VA SG 11201807868V A SG11201807868V A SG 11201807868VA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- cells
- present description
- cell receptors
- peptides
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 7
- 108091008874 T cell receptors Proteins 0.000 title abstract 6
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title abstract 6
- 210000001744 T-lymphocyte Anatomy 0.000 title abstract 5
- 238000009169 immunotherapy Methods 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 6
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 3
- 108700018351 Major Histocompatibility Complex Proteins 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 1
- 150000007513 acids Chemical class 0.000 abstract 1
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000001024 immunotherapeutic effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/464486—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/464488—NY-ESO
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
- C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/55—Lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/57—Skin; melanoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization 11M1111101110101011111 HO 11111 0111310111111101011111001111101111 III N International Bureau .. .... ..Yejd .... ...,,, (10) International Publication Number (43) International Publication Date WO 2017/158103 Al 21 September 2017 (21.09.2017) WIP0 I PCT (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07K 14/435 (2006.01) C12N 15/09 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 35/12 (2015.01) C12N 15/10 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 35/66 (2015.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, PCT/EP2017/056260 KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, (22) International Filing Date: MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, 16 March 2017 (16.03.2017) NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, (25) Filing Language: English TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (26) Publication Language: English ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 1604492.7 16 March 2016 (16.03.2016) GB kind of regional protection available): ARIPO (BW, GH, 62/308,975 16 March 2016 (16.03.2016) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (71) Applicant: IMMATICS BIOTECHNOLOGIES GMBH TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, [DE/DE]; Paul-Ehrlich-StraBe 15, 72076 Tiibingen (DE). DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, (72) Inventors: ALTEN, Leonie; WeiBdornweg 14, App. 161, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, 72076 Tubingen (DE). MAURER, Dominik; Fleinerweg SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, _ 7, 72116 Moessingen (DE). BUNK, Sebastian; Staeudach GW, KM, ML, MR, NE, SN, TD, TG). — 182, 72074 Tiibingen (DE). Published: _ (74) Agent: BOEHMERT & BOEHMERT; Jan B. KRAUSS, — with international search report (Art. 21(3)) = Pettenkoferstrasse 20 - 22, 80336 Munich (DE). — with sequence listing of description (Rule 5.2(a)) part = = = = = = = = = = 1-1 M (54) Title: TRANSFECTED T-CELLS AND T-CELL RECEPTORS FOR USE IN IMMUNOTHERAPY AGAINST CANCERS 0 1-1 (57) : The present description relates to T-cell receptors (TCRs) binding to tumor-associated antigens (TAAs) for targeting GC cancer cells, T-cells expressing same, methods for producing same, and methods for treating cancers using same. In particular, the L i ) present description relates to TCRs and their variants that bind to HLA class I or II molecules with a peptide, such as MAG-003 S have the amino acid sequence of KVLEHVVRV (SEQ ID NO:1). The present description further relates to peptides, proteins, nude- IL— is acids and cells for use in immunotherapeutic methods. In particular, the present description relates to the immunotherapy of can- 1-1 c:::: ) cer. The present description furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other to - N mor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate an - 0 ti-tumor immune responses, or to stimulate T-cells ex vivo and transfer into patients. Peptides bound to molecules of the major histo - compatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding mo - 5. lecules.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662308975P | 2016-03-16 | 2016-03-16 | |
GBGB1604492.7A GB201604492D0 (en) | 2016-03-16 | 2016-03-16 | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers |
PCT/EP2017/056260 WO2017158103A1 (en) | 2016-03-16 | 2017-03-16 | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201807868VA true SG11201807868VA (en) | 2018-10-30 |
Family
ID=55952417
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201807868VA SG11201807868VA (en) | 2016-03-16 | 2017-03-16 | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers |
Country Status (16)
Country | Link |
---|---|
US (1) | US10538573B2 (en) |
EP (1) | EP3430030B1 (en) |
JP (1) | JP7340127B2 (en) |
KR (2) | KR102457504B1 (en) |
CN (1) | CN108884136B (en) |
AU (2) | AU2017235467B2 (en) |
CA (1) | CA3017502A1 (en) |
CR (1) | CR20180492A (en) |
EA (1) | EA201892021A1 (en) |
GB (1) | GB201604492D0 (en) |
MA (2) | MA43330B1 (en) |
MX (1) | MX2018011225A (en) |
MY (1) | MY189042A (en) |
SG (1) | SG11201807868VA (en) |
TW (1) | TWI764886B (en) |
WO (1) | WO2017158103A1 (en) |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6656733B2 (en) | 2013-08-05 | 2020-03-04 | ツイスト バイオサイエンス コーポレーション | Newly synthesized gene library |
US10669304B2 (en) | 2015-02-04 | 2020-06-02 | Twist Bioscience Corporation | Methods and devices for de novo oligonucleic acid assembly |
WO2016172377A1 (en) | 2015-04-21 | 2016-10-27 | Twist Bioscience Corporation | Devices and methods for oligonucleic acid library synthesis |
JP6982362B2 (en) | 2015-09-18 | 2021-12-17 | ツイスト バイオサイエンス コーポレーション | Oligonucleic acid mutant library and its synthesis |
CN108698012A (en) | 2015-09-22 | 2018-10-23 | 特韦斯特生物科学公司 | Flexible substrates for nucleic acid synthesis |
US9895673B2 (en) | 2015-12-01 | 2018-02-20 | Twist Bioscience Corporation | Functionalized surfaces and preparation thereof |
EP4357454A2 (en) * | 2016-03-16 | 2024-04-24 | Immatics Biotechnologies GmbH | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers |
GB2568444A (en) | 2016-08-22 | 2019-05-15 | Twist Bioscience Corp | De novo synthesized nucleic acid libraries |
KR102217487B1 (en) | 2016-09-21 | 2021-02-23 | 트위스트 바이오사이언스 코포레이션 | Nucleic acid-based data storage |
DE102016123847B3 (en) | 2016-12-08 | 2018-04-05 | Immatics Biotechnologies Gmbh | New T cell receptors and their use in immunotherapy |
HUE058957T2 (en) | 2016-12-08 | 2022-10-28 | Immatics Biotechnologies Gmbh | Novel t cell receptors and immune therapy using the same |
CN110366613A (en) * | 2016-12-16 | 2019-10-22 | 特韦斯特生物科学公司 | The Mutant libraries of immunological synapse and its synthesis |
CA3054303A1 (en) | 2017-02-22 | 2018-08-30 | Twist Bioscience Corporation | Nucleic acid based data storage |
WO2018170169A1 (en) | 2017-03-15 | 2018-09-20 | Twist Bioscience Corporation | Variant libraries of the immunological synapse and synthesis thereof |
MA49122A (en) * | 2017-04-10 | 2021-03-24 | Immatics Biotechnologies Gmbh | PEPTIDES AND COMBINATIONS OF PEPTIDES INTENDED FOR USE IN ANTI-CANCER IMMUNOTHERAPY |
WO2018231864A1 (en) | 2017-06-12 | 2018-12-20 | Twist Bioscience Corporation | Methods for seamless nucleic acid assembly |
CA3066744A1 (en) | 2017-06-12 | 2018-12-20 | Twist Bioscience Corporation | Methods for seamless nucleic acid assembly |
SG11202002194UA (en) | 2017-09-11 | 2020-04-29 | Twist Bioscience Corp | Gpcr binding proteins and synthesis thereof |
EP3694872A4 (en) * | 2017-10-12 | 2021-06-30 | Board Of Regents, The University Of Texas System | T cell receptors for immunotherapy |
WO2019079769A1 (en) | 2017-10-20 | 2019-04-25 | Twist Bioscience Corporation | Heated nanowells for polynucleotide synthesis |
US10936953B2 (en) | 2018-01-04 | 2021-03-02 | Twist Bioscience Corporation | DNA-based digital information storage with sidewall electrodes |
GB201803750D0 (en) | 2018-03-08 | 2018-04-25 | Immunocore Ltd | Method |
WO2019196088A1 (en) * | 2018-04-13 | 2019-10-17 | Syz Cell Therapy Co. | Methods of obtaining tumor-specific t cell receptors |
WO2019222706A1 (en) | 2018-05-18 | 2019-11-21 | Twist Bioscience Corporation | Polynucleotides, reagents, and methods for nucleic acid hybridization |
JP2021536578A (en) * | 2018-09-14 | 2021-12-27 | イマティクス バイオテクノロジーズ ゲーエムベーハー | Methods for High Throughput Peptide-MHC Affinity Screening for TCR Ligands |
SG11202109322TA (en) | 2019-02-26 | 2021-09-29 | Twist Bioscience Corp | Variant nucleic acid libraries for glp1 receptor |
JP2022522668A (en) | 2019-02-26 | 2022-04-20 | ツイスト バイオサイエンス コーポレーション | Mutant nucleic acid library for antibody optimization |
WO2020191172A1 (en) | 2019-03-19 | 2020-09-24 | Immatics US, Inc. | Cd28 t cell cultures, compositions, and methods of using thereof |
DE102019108125B4 (en) | 2019-03-28 | 2022-02-03 | Immatics US, Inc. | CD28 T-CELL CULTURES, COMPOSITIONS AND METHODS OF USE |
CN111748029B (en) * | 2019-03-29 | 2022-12-13 | 苏州蓝马医疗技术有限公司 | Specific T cell receptor aiming at EGFR L858R gene mutation and application thereof |
CN111748028A (en) * | 2019-03-29 | 2020-10-09 | 天津亨佳生物科技发展有限公司 | Specific T cell receptor aiming at EGFR L858R gene mutation and application thereof |
MA55911A (en) * | 2019-05-08 | 2022-03-16 | 2Seventy Bio Inc | GENETICALLY MODIFIED T LYMPHOCYTES |
JP2022534716A (en) | 2019-05-27 | 2022-08-03 | イマティクス ユーエス,アイエヌシー. | Viral vectors and their use in adoptive cell therapy |
BR112021025548A2 (en) * | 2019-06-18 | 2022-05-17 | Regeneron Pharma | Mage-a4 t-cell receptors and methods of using them |
AU2020298294A1 (en) | 2019-06-21 | 2022-02-17 | Twist Bioscience Corporation | Barcode-based nucleic acid sequence assembly |
CN110357953B (en) * | 2019-07-17 | 2022-05-03 | 深圳市因诺转化医学研究院 | TCR recognizing human cytomegalovirus pp65 antigen |
MX2022001211A (en) * | 2019-07-30 | 2022-05-03 | Univ Health Network | Mhc class ii molecules and methods of use thereof. |
DE102019121007A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Antigen binding proteins that specifically bind to MAGE-A |
US20210032370A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
JP2023515131A (en) | 2020-02-24 | 2023-04-12 | イマティクス ユーエス,アイエヌシー. | Methods of expanding T cells for the treatment of cancer and related malignancies |
DE102020111571A1 (en) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | WPRE MUTANT CONSTRUCTS, COMPOSITIONS, AND RELATED PROCEDURES |
TW202227616A (en) * | 2020-08-21 | 2022-07-16 | 美商英麥提克斯股份有限公司 | Methods for isolating cd8+ selected t cells |
EP4227316A1 (en) * | 2020-10-07 | 2023-08-16 | Daan Biotherapeutics Co., Ltd. | T cell receptor, immune cell comprising t cell receptor, and method using same |
EP4271481A2 (en) | 2020-12-31 | 2023-11-08 | Immatics US, Inc. | Cd8 polypeptides, compositions, and methods of using thereof |
DE102021100038A1 (en) | 2020-12-31 | 2022-06-30 | Immatics US, Inc. | MODIFIED CD8 POLYPEPTIDES, COMPOSITIONS AND METHODS OF USE THEREOF |
CN115975003B (en) * | 2021-03-09 | 2024-01-26 | 科士华(南京)生物技术有限公司 | TCR, polypeptide, expression vector, host cell, pharmaceutical composition and TCR obtaining method |
EP4326751A1 (en) * | 2021-04-21 | 2024-02-28 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Hla class i-restricted t cell receptors against ras with q61k mutation |
CA3217739A1 (en) | 2021-05-05 | 2022-11-10 | Sebastian Bunk | Bma031 antigen binding polypeptides |
CN113337514B (en) * | 2021-08-05 | 2021-10-29 | 卡瑞济(北京)生命科技有限公司 | TCR expression constructs and methods of making and using the same |
WO2023044488A1 (en) | 2021-09-20 | 2023-03-23 | Immatics US, Inc. | Monocyte depletion of t cells populations for t-cell therapy |
CN113773378B (en) * | 2021-10-14 | 2023-11-03 | 深圳大学总医院 | T cell receptor and application thereof |
US20230192886A1 (en) | 2021-11-08 | 2023-06-22 | Immatics Biotechnologies Gmbh | Adoptive cell therapy combination treatment and compositions thereof |
US20230142468A1 (en) | 2021-11-08 | 2023-05-11 | Immatics US, Inc. | Methods for generating cell spheroids |
WO2023137472A2 (en) | 2022-01-14 | 2023-07-20 | Tune Therapeutics, Inc. | Compositions, systems, and methods for programming t cell phenotypes through targeted gene repression |
WO2023137471A1 (en) | 2022-01-14 | 2023-07-20 | Tune Therapeutics, Inc. | Compositions, systems, and methods for programming t cell phenotypes through targeted gene activation |
WO2023148494A1 (en) * | 2022-02-03 | 2023-08-10 | University College Cardiff Consultants Limited | Novel t-cell receptor |
WO2023183758A2 (en) * | 2022-03-19 | 2023-09-28 | Regeneron Pharmaceuticals, Inc. | Multispecific molecules targeting cd3 and mage-a4 and uses thereof |
US20240066127A1 (en) | 2022-04-28 | 2024-02-29 | Immatics US, Inc. | Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof |
WO2023212691A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | DOMINANT NEGATIVE TGFβ RECEPTOR POLYPEPTIDES, CD8 POLYPEPTIDES, CELLS, COMPOSITIONS, AND METHODS OF USING THEREOF |
WO2023212697A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
WO2023215825A1 (en) | 2022-05-05 | 2023-11-09 | Immatics US, Inc. | Methods for improving t cell efficacy |
WO2023250168A2 (en) * | 2022-06-24 | 2023-12-28 | Amgen Inc. | Magea4 specific t cell receptors |
WO2024036166A1 (en) * | 2022-08-08 | 2024-02-15 | The University Of North Carolina At Chapel Hill | Bioorthogonal t cell receptor molecules and methods of making and using the same |
WO2024064642A2 (en) | 2022-09-19 | 2024-03-28 | Tune Therapeutics, Inc. | Compositions, systems, and methods for modulating t cell function |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101130597B1 (en) * | 2005-09-13 | 2012-04-02 | 다카라 바이오 가부시키가이샤 | T-cell receptor and nucleic acid encoding the receptor |
WO2008053573A1 (en) * | 2006-10-30 | 2008-05-08 | National University Corporation Hokkaido University | Remedy for malignant neoplasm |
LT2618835T (en) | 2010-09-20 | 2017-10-10 | Biontech Cell & Gene Therapies Gmbh | Antigen-specific t cell receptors and t cell epitopes |
KR20140033029A (en) * | 2011-04-01 | 2014-03-17 | 메모리얼 슬로안-케터링 캔서 센터 | T cell receptor-like antibodies specific for a wt1 peptide presented by hla-a2 |
CA2847332A1 (en) * | 2011-08-31 | 2013-03-07 | Mie University | Vaccine preparation for cancer treatment |
WO2013057596A1 (en) | 2011-10-21 | 2013-04-25 | Atena Srl | Anatomic cushion accumulator for thermal treatment with heat or cold |
GB2508414A (en) * | 2012-11-30 | 2014-06-04 | Max Delbrueck Centrum | Tumour specific T cell receptors (TCRs) |
JP6164759B2 (en) | 2013-11-21 | 2017-07-19 | Repertoire Genesis株式会社 | Analysis system for T cell receptor and B cell receptor repertoire and its use for therapy and diagnosis |
US10202640B2 (en) * | 2014-05-07 | 2019-02-12 | The Board Of Trustees Of The Leland Stanford Junior University | Single cell analysis of T cells using high-throughput multiplex amplification and deep sequencing |
-
2016
- 2016-03-16 GB GBGB1604492.7A patent/GB201604492D0/en not_active Ceased
-
2017
- 2017-03-16 SG SG11201807868VA patent/SG11201807868VA/en unknown
- 2017-03-16 KR KR1020217015786A patent/KR102457504B1/en active IP Right Grant
- 2017-03-16 MA MA43330A patent/MA43330B1/en unknown
- 2017-03-16 CR CR20180492A patent/CR20180492A/en unknown
- 2017-03-16 MY MYPI2018703216A patent/MY189042A/en unknown
- 2017-03-16 MA MA043720A patent/MA43720A/en unknown
- 2017-03-16 KR KR1020187029016A patent/KR102259109B1/en active IP Right Grant
- 2017-03-16 EA EA201892021A patent/EA201892021A1/en unknown
- 2017-03-16 US US15/460,654 patent/US10538573B2/en active Active
- 2017-03-16 WO PCT/EP2017/056260 patent/WO2017158103A1/en active Application Filing
- 2017-03-16 EP EP17710955.0A patent/EP3430030B1/en active Active
- 2017-03-16 MX MX2018011225A patent/MX2018011225A/en unknown
- 2017-03-16 JP JP2018548022A patent/JP7340127B2/en active Active
- 2017-03-16 TW TW106108700A patent/TWI764886B/en active
- 2017-03-16 CA CA3017502A patent/CA3017502A1/en active Pending
- 2017-03-16 CN CN201780017511.6A patent/CN108884136B/en active Active
- 2017-03-16 AU AU2017235467A patent/AU2017235467B2/en active Active
-
2021
- 2021-07-07 AU AU2021204753A patent/AU2021204753A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2017235467A1 (en) | 2018-11-01 |
GB201604492D0 (en) | 2016-04-27 |
CN108884136B (en) | 2023-03-17 |
EP3430030A1 (en) | 2019-01-23 |
KR102457504B1 (en) | 2022-10-20 |
MA43720A (en) | 2018-11-28 |
KR102259109B1 (en) | 2021-06-01 |
MX2018011225A (en) | 2018-11-22 |
AU2017235467B2 (en) | 2021-04-08 |
KR20180118783A (en) | 2018-10-31 |
JP2019511222A (en) | 2019-04-25 |
TWI764886B (en) | 2022-05-21 |
MY189042A (en) | 2022-01-21 |
MA43330A1 (en) | 2019-07-31 |
US10538573B2 (en) | 2020-01-21 |
JP7340127B2 (en) | 2023-09-07 |
AU2021204753A1 (en) | 2021-08-05 |
EA201892021A1 (en) | 2019-02-28 |
TW201736396A (en) | 2017-10-16 |
MA43330B1 (en) | 2020-06-30 |
WO2017158103A1 (en) | 2017-09-21 |
EP3430030B1 (en) | 2023-12-20 |
CA3017502A1 (en) | 2017-09-21 |
CN108884136A (en) | 2018-11-23 |
CR20180492A (en) | 2019-01-31 |
KR20210063486A (en) | 2021-06-01 |
US20170267738A1 (en) | 2017-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201807868VA (en) | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers | |
SG11201807590SA (en) | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers | |
SG11201806905UA (en) | Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers | |
SG11201807300PA (en) | Uterine cancer treatments | |
SG11201806951TA (en) | Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers | |
SG11201900955VA (en) | T cell receptors and immune therapy using the same | |
SG11201806577UA (en) | Novel peptides and combination of peptides for use in immunotherapy against nhl and other cancers | |
SG11201906198PA (en) | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | |
SG11201908023YA (en) | T cell receptors and immune therapy using the same against prame positive cancers | |
SG11201801384YA (en) | Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers | |
SG11201801670YA (en) | Novel peptides and combination of peptides for use in immunotherapy against cll and other cancers | |
SG11201801756WA (en) | Novel peptides and combination of peptides for use in immunotherapy against various cancers | |
SG11201909153UA (en) | Peptides and combination thereof for use in the immunotherapy against cancers | |
SG11201809781PA (en) | Novel peptides, combination of peptides as targets and for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers | |
SG11201908527SA (en) | High affinity mage-a1-specific tcrs and uses thereof | |
SG11201808783XA (en) | Cd80 variant immunomodulatory proteins and uses thereof | |
SG11201903021WA (en) | Anti-human 4-1 bb antibodies and use thereof | |
SG11201806150RA (en) | Psma and cd3 bispecific t cell engaging antibody constructs | |
SG11201807279QA (en) | Binding proteins and methods of use thereof | |
SG11201808710UA (en) | Novel immunogenic cd1d binding peptides | |
SG11201810933QA (en) | Anti-c5 antibodies and uses thereof | |
SG11201804839WA (en) | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof | |
SG11201907580SA (en) | Combination therapies for treatment of bcma-related cancers and autoimmune disorders | |
SG11201909058WA (en) | Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers | |
SG11201810697QA (en) | Chimeric antigen receptor and car-t cells that bind bcma |